

Project Short Description

Appraisal Board

Project Lead: Sabine Geiger-Gritsch

Authors: Sarah Wolf, Michaela Riegelneegg, Naomi Linton-Romir, Alba Colicchia, Diana Szivakova, Eleen Rothschedl, Eva Malikova, Daniel Fabian, Tatiana Marschik

Duration: Ongoing

Publication: Continuous

Language: English

Content:

As part of the recent reform of the Austrian healthcare system, the establishment of an Appraisal Board for selected high-cost and specialized medicinal products, as well as other highly specialized therapies in the intramural setting or at the interface between intra- and extramural care, has been legally mandated. The operational implementation of the Appraisal Board, along with its alignment with the EU HTA Regulation, requires a range of preparatory and ongoing activities.

In 2026, AIHTA will continue to support the administrative office at the ministry in the following areas:

- Continuous expansion of a database of clinical experts across various specialties
- Development of a methods and process manual,
- Creation of a methodological guideline for health economic evaluations (see RA health economics)
- Support for the prioritization of medicinal products (longlists, fact sheets, shortlists, etc.)
- Conducting HTAs, taking into account, where available, European Joint Clinical Assessments (JCAs) for medicinal products selected by the Evaluation Board (for 2026: 5 HTAs)
- Coordinating PICO-Surveys for JCAs on medicinal products in the hospital setting